A Comprehensive Monograph on Apalutamide (Erleada): Pharmacology, Clinical Efficacy, and Therapeutic Placement in Prostate Cancer

I. Executive Summary

Apalutamide is a potent, second-generation, nonsteroidal androgen receptor (AR) inhibitor that has become a standard of care in the management of advanced prostate cancer. Marketed under the brand name Erleada, this small molecule therapeutic represents a significant evolution in hormonal therapy, offering a more comprehensive blockade of the AR signaling pathway compared to its first-generation predecessors. Its clinical development culminated in landmark approvals by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for two distinct and critical patient populations: those with non-metastatic castration-resistant prostate cancer (nmCRPC) and those with metastatic castration-sensitive prostate cancer (mCSPC).

The approval for nmCRPC was based on the pivotal Phase 3 SPARTAN trial, which demonstrated that apalutamide, when added to androgen deprivation therapy (ADT), dramatically reduced the risk of metastasis or death by 72% and extended median metastasis-free survival (MFS) by over two years compared to ADT alone. This trial was notable not only for its robust efficacy but also for establishing MFS as a valid surrogate endpoint for regulatory approval in this disease state, a precedent that accelerated subsequent drug development in the field. The final analysis of SPARTAN later confirmed a significant overall survival (OS) benefit.

For mCSPC, the Phase 3 TITAN trial established apalutamide's efficacy, showing that its addition to ADT reduced the risk of death by 35% and significantly improved radiographic progression-free survival (rPFS). Critically, this profound survival benefit was achieved while preserving patients' health-related quality of life, addressing a key concern in the early intensification of cancer therapy.

Pharmacokinetically, apalutamide exhibits a favorable profile characterized by 100% oral bioavailability, a long half-life supporting convenient once-daily dosing with or without food, and limited central nervous system penetration. Its safety profile is well-characterized, with common adverse events including fatigue, hypertension, rash, falls, and fractures. The risk of falls and fractures necessitates proactive patient monitoring and management of bone health. A defining feature of apalutamide is its potent induction of metabolic enzymes (notably CYP3A4 and CYP2C19) and drug transporters, creating a significant potential for drug-drug interactions that requires careful management of concomitant medications.

Within the competitive landscape of second-generation AR inhibitors, which includes enzalutamide and darolutamide, the selection of apalutamide involves a nuanced clinical decision. It offers potent efficacy, while its competitors may present different tolerability and drug-interaction profiles. The choice of agent is therefore guided by a careful assessment of individual patient characteristics, including comorbidities, frailty, and concomitant medication use. Apalutamide stands as a cornerstone therapy in advanced prostate cancer, and future research is focused on personalizing its use through biomarkers and exploring its efficacy in novel combinations and earlier disease settings.

II. Molecular Profile and Physicochemical Properties

A precise understanding of a therapeutic agent begins with its fundamental chemical identity. The molecular profile of apalutamide provides the foundational information for its classification, synthesis, and interaction with biological systems.

Drug Identification

Apalutamide is a small molecule drug that has been assigned multiple identifiers throughout its development and commercialization, reflecting its journey from a research compound to a globally marketed pharmaceutical.[1]

• Generic Name: Apalutamide.[1]
• Brand Names: It is marketed commercially under the brand names Erleada and Erlyand.[2]
• Drug Type: Small Molecule.[1]
• Development Codes & Synonyms: During its preclinical and clinical development, apalutamide was known by the research code ARN-509. Following its acquisition and further development, it was also assigned the code JNJ-56021927.[1] These codes are frequently referenced in early scientific literature and clinical trial registries. The progression from the "ARN" designation, associated with its originating developer Aragon Pharmaceuticals, to the "JNJ" code and the brand name Erleada, reflects a classic and successful pharmaceutical development pathway involving discovery by a specialized firm followed by acquisition and large-scale commercialization by a global pharmaceutical company, Janssen, a division of Johnson & Johnson.[2]
• Database Identifiers: To ensure unambiguous identification across global databases, apalutamide is cataloged with numerous unique codes, including:
• DrugBank ID: DB11901.[1]
• CAS Number: 956104-40-8.[2]
• PubChem CID: 24872560.[2]
• Other Identifiers: A comprehensive list of identifiers includes its UNII (4T36H88UA7), KEGG (D11040), and ChEMBL (CHEMBL3183409) codes, among others, facilitating cross-referencing in chemical, biological, and regulatory databases.[2]

Chemical and Structural Properties

The specific chemical structure and properties of apalutamide are responsible for its high-affinity binding to the androgen receptor and its overall pharmacokinetic behavior.

• Chemical Formula: The empirical formula for apalutamide is C21​H15​F4​N5​O2​S.[1]
• Molecular Weight: The average molecular weight is 477.44 g·mol⁻¹, with a monoisotopic mass of 477.088258569 Da.[1]
• IUPAC Name: The systematic chemical name is 4-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide.[2]
• Structural Codes: For computational chemistry and database searching, its structure is represented by codes such as:
• SMILES: CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(N=C4)C#N)C(F)(F)F)F.[5]
• InChIKey: HJBWBFZLDZWPHF-UHFFFAOYSA-N.[2]
• Physical Appearance and Formulation: Apalutamide is described as a white to off-white solid powder or crystalline solid.[6] It is commercially available for research purposes in amorphous and Form B polymorphic states.[12] It is formulated for clinical use as film-coated oral tablets.[11]

The following table consolidates the key identification and physicochemical properties of apalutamide for reference.

Table 1: Apalutamide Drug Identification and Chemical Properties

Property	Value	Source(s)
Generic Name	Apalutamide	1
Brand Names	Erleada, Erlyand	2
Drug Type	Small Molecule	1
Development Codes	ARN-509, JNJ-56021927	1
DrugBank ID	DB11901	1
CAS Number	956104-40-8	2
Chemical Formula	C21​H15​F4​N5​O2​S	1
Average Molecular Weight	477.44 g·mol⁻¹	1
IUPAC Name	4-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl]-2-fluoro-N-methylbenzamide	2
Physical Appearance	White to off-white solid powder	6

III. Pharmacodynamics: Mechanism of Potent Androgen Receptor Inhibition

The therapeutic efficacy of apalutamide in prostate cancer is rooted in its potent and comprehensive antagonism of the androgen receptor (AR) signaling pathway. Persistent AR signaling is a key driver of disease progression, even in the castration-resistant state, where it can be maintained through mechanisms such as AR gene amplification, mutation, or overexpression.[1] Apalutamide was specifically designed to overcome the limitations of first-generation antiandrogens and provide a more complete shutdown of this critical oncogenic pathway.

Primary Target and Binding Affinity

Apalutamide is a selective, competitive antagonist of the androgen receptor.[1] It binds with high affinity directly to the ligand-binding domain (LBD) of the AR. In cell-free biochemical assays, it demonstrates a half-maximal inhibitory concentration (

IC50​) of 16 nM.[1] This binding affinity is reported to be approximately 7- to 10-fold greater than that of bicalutamide, a first-generation nonsteroidal antiandrogen (NSAA), signifying a substantial improvement in target engagement.[2]

Comprehensive Mechanism of Action

Unlike older agents which can exhibit partial agonist activity, apalutamide functions as a "silent antagonist".[2] This means that upon binding to the AR, it does not induce a conformational change that promotes transcriptional activity. This is particularly crucial in the context of castration-resistant prostate cancer (CRPC), where AR overexpression can cause first-generation antagonists to paradoxically stimulate tumor growth.[1]

Apalutamide exerts its potent antitumor effect by disrupting the AR signaling cascade at multiple, sequential steps, effectively preventing the receptor from carrying out its function as a ligand-activated transcription factor [1]:

1. Inhibition of Ligand Binding: It competitively blocks the binding of endogenous androgens, such as testosterone and its more potent metabolite dihydrotestosterone (DHT), to the AR's ligand-binding domain.
2. Prevention of AR Nuclear Translocation: Following androgen binding, the AR typically translocates from the cytoplasm to the nucleus to act on DNA. Apalutamide binding prevents this critical step, sequestering the receptor in the cytoplasm and forming inactive complexes.[1]
3. Impediment of DNA Binding and Gene Transcription: For any residual AR that may reach the nucleus, apalutamide obstructs its ability to bind to specific DNA sequences known as androgen response elements (AREs). This blockade prevents the recruitment of coactivators and the initiation of transcription for a host of AR-regulated genes that are essential for prostate cancer cell growth and survival, such as prostate-specific antigen (PSA) and transmembrane protease, serine 2 (TMPRSS2).[5]

In vitro studies have confirmed this comprehensive mechanism. In prostate cancer cell lines, apalutamide effectively inhibits androgen-mediated gene expression and proliferation.[5] It has been shown to impair AR nuclear localization and effectively compete with synthetic androgens to prevent the AR from binding to promoter regions on DNA.[7]

Off-Target Activity and Comparative Considerations

While highly selective for the AR, apalutamide does exhibit some off-target activity. Notably, it has a weak binding affinity for the GABA-A receptor, with an IC50​ of approximately 3.0 µM in radioligand binding assays.[2] This is pharmacologically relevant because inhibition of the GABA-A receptor in the central nervous system (CNS) is associated with a lowered seizure threshold.

This characteristic is shared with its close structural and pharmacological relative, enzalutamide, which has a similar weak affinity for the GABA-A receptor (IC50​ ≈ 2.7 µM).[2] However, a critical distinction between the two drugs arises from their pharmacokinetic properties. Apalutamide was designed to have a several-fold reduced distribution into the CNS compared to enzalutamide.[2] The clinical implication of this design is significant: because lower concentrations of apalutamide reach the brain, its potential to antagonize GABA-A receptors

in vivo at therapeutic doses is reduced. This interplay between a shared pharmacodynamic off-target effect and a differentiating pharmacokinetic property likely contributes to a lower observed clinical risk of seizures with apalutamide compared to enzalutamide, a key point of differentiation within the therapeutic class.[2]

IV. Clinical Pharmacology: A Comprehensive Pharmacokinetic Profile

The pharmacokinetic (PK) profile of a drug, encompassing its absorption, distribution, metabolism, and excretion (ADME), is a critical determinant of its dosing regimen, efficacy, and potential for interactions. Apalutamide possesses a largely favorable PK profile that supports a convenient and reliable dosing schedule for long-term cancer therapy.

Absorption and Distribution

• Oral Bioavailability: Apalutamide exhibits a high mean absolute oral bioavailability of 100%, ensuring complete and predictable absorption after oral administration.[2]
• Time to Peak Concentration (Tmax​): Under fasting conditions, mean peak plasma concentrations of apalutamide are achieved approximately 2 hours after a dose, with a range of 1 to 5 hours.[2]
• Food Effect: The administration of apalutamide with a high-fat meal (approximately 800-1000 calories) does not result in any clinically relevant changes to its peak concentration (Cmax​) or total exposure (Area Under the Curve, AUC). While food may delay the median Tmax​ by approximately 2 hours, the lack of impact on overall exposure allows for flexible dosing with or without food, which can significantly enhance patient convenience and adherence.[1]
• Plasma Protein Binding: Apalutamide is extensively bound to plasma proteins, primarily albumin, with a bound fraction of 96%. Its major active metabolite, N-desmethylapalutamide, is similarly highly bound at 95%.[2] This high degree of binding limits the amount of free, active drug but contributes to its long half-life.
• Central Nervous System (CNS) Penetration: A defining feature of apalutamide's distribution profile is its limited penetration across the blood-brain barrier. This property was an intentional design element to differentiate it from enzalutamide and is believed to contribute to its more favorable CNS side effect profile, particularly regarding the risk of seizures.[2]

Metabolism and Excretion

• Metabolism: Apalutamide is primarily cleared from the body via hepatic metabolism. The major enzymatic pathways involved are oxidation by cytochrome P450 (CYP) enzymes, specifically CYP2C8 and CYP3A4. At steady-state, both enzymes contribute to a similar extent to the formation of its primary metabolite.[2]
• Active Metabolite: This metabolic process forms a major active metabolite, N-desmethylapalutamide. This metabolite also possesses antiandrogenic activity and contributes to the overall therapeutic effect of the drug.[2]
• Elimination Half-Life (t1/2​): Apalutamide has a long terminal elimination half-life of approximately 3 to 4 days at steady-state.[2] This long half-life is a key factor enabling its once-daily dosing regimen.
• Steady State and Accumulation: Due to its long half-life, repeated daily dosing leads to an accumulation of the drug in the plasma. Steady-state concentrations are typically achieved after 4 weeks of continuous administration, with an approximate 5-fold accumulation compared to a single dose.[2] This results in stable plasma concentrations throughout the dosing interval, with low peak-to-trough fluctuation ratios (e.g., 1.63 for apalutamide), ensuring consistent target engagement and sustained therapeutic pressure on the tumor.[2]
• Excretion: Following extensive metabolism, the byproducts of apalutamide are eliminated from the body primarily in the urine. Approximately 89% of a dose is recovered over time, with 65% found in the urine (1.2% as unchanged apalutamide, 2.7% as N-desmethylapalutamide) and 24% in the feces (1.5% as unchanged apalutamide, 2% as N-desmethylapalutamide).[2]

The combination of 100% oral bioavailability, a long half-life enabling once-daily dosing, and the absence of a significant food effect provides a near-ideal pharmacokinetic profile for a chronic oral anticancer agent. These characteristics directly translate into a convenient, forgiving regimen that promotes high patient adherence and ensures reliable, consistent drug exposure, which are critical factors for success in long-term therapy, especially in an elderly patient population.

Table 2: Summary of Apalutamide Pharmacokinetic Parameters

Parameter	Value	Source(s)
Oral Bioavailability	100%	2
Tmax​ (Fasting)	~2 hours (range: 1-5 hours)	2
Food Effect	No clinically relevant effect on AUC or Cmax​	1
Plasma Protein Binding	96% (Apalutamide); 95% (N-desmethyl metabolite)	2
Metabolizing Enzymes	CYP2C8, CYP3A4	2
Major Active Metabolite	N-desmethylapalutamide	2
Elimination Half-Life (t1/2​)	3-4 days (at steady-state)	2
Time to Steady State	4 weeks	2
Excretion	65% Urine, 24% Feces	2

V. Clinical Efficacy in Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC): Analysis of the SPARTAN Trial

The approval of apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC) was a landmark event, establishing a new standard of care for a previously unmet clinical need and setting a new regulatory precedent. The pivotal Phase 3 SPARTAN trial provided the definitive evidence for its efficacy in this setting.

Trial Design and Patient Population

• Study Name: SPARTAN (NCT01946204).[10]
• Design: A large-scale, Phase 3, multicenter, randomized (in a 2:1 ratio), double-blind, placebo-controlled clinical trial. This design represents the highest level of evidence for evaluating a new therapeutic intervention.[10]
• Patient Population: The trial enrolled 1,207 men with nmCRPC who were deemed to be at high risk for developing overt metastases. This high-risk status was defined by a rapidly rising prostate-specific antigen (PSA) level, specifically a PSA doubling time (PSADT) of 10 months or less, while on continuous androgen deprivation therapy (ADT).[19] These patients represent a population in urgent need of intervention to delay the morbid consequences of metastatic disease.
• Intervention: Patients were randomized to receive either apalutamide at a dose of 240 mg orally once daily in combination with their ongoing ADT, or a matching placebo plus ADT.[10]

Efficacy Outcomes: From Metastasis-Free to Overall Survival

The SPARTAN trial was designed to measure clinically meaningful delays in disease progression and, ultimately, improvements in survival.

• Primary Endpoint (Metastasis-Free Survival - MFS): The primary outcome was MFS, defined as the time from randomization to the first evidence of distant metastasis or death from any cause. The results were unequivocally positive.
• The initial analysis revealed that apalutamide profoundly prolonged the median MFS to 40.5 months, compared to just 16.2 months for patients receiving placebo. This represents a remarkable delay of more than two years.[11]
• Statistically, this translated to a 72% reduction in the risk of metastasis or death, with a Hazard Ratio (HR) of 0.28 (95% Confidence Interval [CI]: 0.23-0.35; p<0.0001).[9] The extremely low p-value indicates a very high degree of statistical certainty in the result.
• Key Secondary Endpoint (Overall Survival - OS): While the MFS data were mature enough for the initial approval, the data for the key secondary endpoint of overall survival were immature at the time of the primary analysis.[22] A prespecified final analysis was conducted later to assess the drug's impact on longevity.
• With a median follow-up of 52 months, the final analysis demonstrated a statistically significant benefit in OS. The median OS was 73.9 months for patients in the apalutamide group versus 59.9 months for those in the placebo group, an absolute improvement of 14 months.[23]
• This corresponded to a 22% reduction in the risk of death (HR: 0.78; 95% CI: 0.64-0.96; p=0.016).[23] This survival benefit is particularly compelling given that 19% of patients in the placebo group were allowed to cross over and receive open-label apalutamide after the study was unblinded, and a high proportion (84%) of the placebo group went on to receive subsequent life-prolonging therapies. These factors would tend to dilute the observed OS difference, suggesting the true treatment effect may be even greater.[22]
• Other Endpoints: In addition to the primary and key secondary endpoints, apalutamide also demonstrated statistically significant improvements in other important measures of disease control, including the time to metastasis, progression-free survival (PFS), and time to symptomatic progression, reinforcing the comprehensive clinical benefit of the treatment.[9]

The regulatory approval of apalutamide based on the SPARTAN trial's MFS endpoint was a paradigm-shifting event. Prior to this, there were no approved therapies for nmCRPC, and demonstrating an OS benefit in this non-metastatic population was a lengthy and challenging process. The FDA's decision to approve a drug based on MFS validated this endpoint as a clinically meaningful surrogate for OS in this specific disease context. As noted by Dr. Richard Pazdur, Director of the FDA's Oncology Center of Excellence, "This approval is the first to use the endpoint of metastasis-free survival... In the trial supporting approval, Erleada had a robust effect on this endpoint".[16] This landmark decision not only provided a critical new treatment option for patients but also created a new, more efficient regulatory pathway. This directly enabled and streamlined the subsequent development and approval of other drugs in the class, such as enzalutamide and darolutamide, for the same indication, fundamentally transforming the treatment landscape for men with high-risk nmCRPC.

Table 3: Key Efficacy Outcomes of the SPARTAN Trial (nmCRPC)

Endpoint	Apalutamide + ADT	Placebo + ADT	Hazard Ratio (95% CI)	p-value	Source(s)
Median MFS (Primary)	40.5 months	16.2 months	0.28 (0.23 - 0.35)	< 0.0001	19
Median OS (Final Analysis)	73.9 months	59.9 months	0.78 (0.64 - 0.96)	0.016	23

VI. Clinical Efficacy in Metastatic Castration-Sensitive Prostate Cancer (mCSPC): Analysis of the TITAN Trial

Following its success in the castration-resistant setting, apalutamide was investigated in an earlier stage of advanced disease: metastatic castration-sensitive prostate cancer (mCSPC). The Phase 3 TITAN trial was designed to determine if intensifying upfront treatment by adding apalutamide to standard ADT could improve outcomes for this broader patient population.

Trial Design and Patient Population

• Study Name: TITAN (NCT02489318).[24]
• Design: A large, Phase 3, multinational, randomized (in a 1:1 ratio), double-blind, placebo-controlled trial.[24]
• Patient Population: The trial enrolled 1,052 men with mCSPC. The study was designed to be broadly representative of the clinical population, including patients with both high-volume and low-volume metastatic disease, as well as a subset of patients (11%) who had previously received a limited course of docetaxel chemotherapy for their mCSPC.[17]
• Intervention: Patients were randomized to receive either apalutamide 240 mg once daily plus standard ADT, or a matching placebo plus ADT.[24]

Dual Primary and Secondary Efficacy Outcomes

The TITAN trial was designed with two primary endpoints to capture the full spectrum of clinical benefit: radiographic progression-free survival and overall survival.

• Co-Primary Endpoint (Overall Survival - OS): The addition of apalutamide to ADT resulted in a profound improvement in overall survival.
• The final analysis, conducted with a median follow-up of 44 months, confirmed a highly statistically significant OS benefit. Apalutamide reduced the risk of death by 35% compared to placebo (HR: 0.65; 95% CI: 0.53-0.79; p<0.0001).[27]
• The median OS was not reached in the apalutamide arm, as more than half the patients were still alive at the time of analysis, while the median OS for the placebo arm was 52.2 months.[27]
• At the 48-month mark, 65.1% of patients in the apalutamide group were alive, compared to 51.8% in the placebo group.[27] The survival benefit was consistent across all prespecified patient subgroups, including those with high- or low-volume disease and those with or without prior docetaxel treatment.[17]
• Co-Primary Endpoint (Radiographic Progression-Free Survival - rPFS): Apalutamide also demonstrated a major improvement in controlling disease progression.
• The trial showed that apalutamide significantly improved rPFS, reducing the risk of radiographic progression or death by 52% (HR: 0.48; 95% CI: 0.39-0.60; p<0.0001).[24]
• The median rPFS was not reached in the apalutamide arm, versus 22.1 months in the placebo arm, indicating a durable and long-lasting disease control benefit.[24]
• Patient-Reported Outcomes (PROs) / Health-Related Quality of Life (HRQoL): A critical question when intensifying therapy is the impact on patient quality of life. The TITAN trial rigorously assessed this using validated instruments.
• The results showed that despite the addition of a potent AR inhibitor and its associated side effects, apalutamide treatment was associated with the preservation of overall health-related quality of life.[25]
• Analyses of patient-reported pain intensity, pain interference, fatigue, and overall well-being (using the FACT-P questionnaire) showed no significant difference in the time to deterioration between the apalutamide and placebo groups.[25]

The findings from the TITAN trial, particularly the HRQoL data, carry significant clinical weight. They demonstrate that early, upfront intensification of systemic therapy in the metastatic hormone-sensitive setting can produce a substantial survival advantage without imposing an undue burden of toxicity or a decline in quality of life on the patient. This addresses a central goal of modern oncology, which is to extend not just the quantity but also the quality of life. This evidence alleviates the common concern among clinicians and patients that a more effective treatment must invariably lead to a more difficult patient experience. It reframes the conversation around early treatment intensification from a simple survival trade-off to a more holistic clinical benefit, making it a highly attractive option for a broad range of patients with mCSPC.

Table 4: Key Efficacy Outcomes of the TITAN Trial (mCSPC)

Endpoint	Apalutamide + ADT	Placebo + ADT	Hazard Ratio (95% CI)	p-value	Source(s)
Median OS (Co-Primary, Final)	Not Reached	52.2 months	0.65 (0.53 - 0.79)	< 0.0001	27
Median rPFS (Co-Primary)	Not Reached	22.1 months	0.48 (0.39 - 0.60)	< 0.0001	24

VII. Comprehensive Safety and Tolerability Profile

A thorough understanding of a drug's safety profile is essential for its appropriate clinical use, enabling clinicians to anticipate, monitor, and manage potential toxicities. The safety of apalutamide has been extensively characterized in its large, placebo-controlled Phase 3 trials (SPARTAN and TITAN) and through post-marketing surveillance.

Common Adverse Reactions

The most frequently observed adverse reactions (defined as occurring in ≥10% of patients) associated with apalutamide treatment are generally consistent across its approved indications. These include [2]:

• General: Fatigue, feeling very tired.
• Cardiovascular: Hypertension (high blood pressure), hot flush.
• Dermatologic: Rash.
• Gastrointestinal: Diarrhea, nausea.
• Metabolic: Decreased appetite, weight decreased.
• Musculoskeletal: Arthralgia (joint pain).
• Injury/Procedural: Fall, fracture.

Of these, rash is a particularly notable side effect, with an incidence of 25-28% in major trials. While most cases are mild to moderate, Grade 3 or 4 rash occurred in approximately 6% of patients, sometimes requiring dose interruption or reduction.[13]

Clinically Significant Warnings and Precautions

Beyond the common side effects, the prescribing information for apalutamide carries several important warnings regarding serious potential risks that require careful monitoring and management.

• Cerebrovascular and Ischemic Cardiovascular Events: An increased incidence of ischemic heart disease (e.g., myocardial infarction) and cerebrovascular events (e.g., stroke) has been observed in patients treated with apalutamide. Some of these events have been fatal. This necessitates close monitoring for signs and symptoms of these disorders and optimization of underlying cardiovascular risk factors such as hypertension, diabetes, and dyslipidemia.[13]
• Falls and Fractures: Apalutamide treatment is associated with a significantly increased risk of both falls and subsequent fractures. In the SPARTAN trial, for example, falls occurred in 16% of patients on apalutamide versus 9% on placebo, and fractures occurred in 12% versus 7%, respectively.[2] This elevated risk is not an independent toxicity but rather a downstream consequence of the drug's potent mechanism of action. Potent AR inhibition can accelerate the loss of bone mineral density and contribute to muscle weakness (sarcopenia), increasing frailty. This heightened frailty leads to a greater propensity for falls, and in an elderly population with compromised bone health, falls are more likely to result in fractures. This interconnected causal chain underscores the importance of a holistic management approach that includes proactive evaluation of fall and fracture risk, routine bone density monitoring, and consideration of bone-targeted agents (e.g., bisphosphonates, denosumab) as per established guidelines.[16]
• Seizure: A rare but serious neurologic risk is seizure, which occurred in approximately 0.4% of patients treated with apalutamide across the SPARTAN and TITAN studies.[2] Patients with a history of seizures were excluded from these trials, and the drug should be permanently discontinued in any patient who develops a seizure during treatment.
• Severe Cutaneous Adverse Reactions (SCARs): Although rare, fatal and life-threatening cases of SCARs have been reported in patients receiving apalutamide. These include Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS). Any patient presenting with signs of a progressive, severe rash, particularly if accompanied by blistering, mucosal lesions, or systemic symptoms, requires immediate discontinuation of the drug and urgent medical evaluation.[30]
• Interstitial Lung Disease (ILD)/Pneumonitis: Rare but potentially fatal cases of ILD or pneumonitis have occurred. Patients presenting with new or worsening respiratory symptoms should be evaluated promptly, and apalutamide should be permanently discontinued if ILD/pneumonitis is diagnosed.[30]
• Hypothyroidism: Acquired hypothyroidism was reported in 8% of apalutamide-treated patients versus 1.5% of placebo-treated patients in the pivotal trials. This requires monitoring of thyroid function (e.g., TSH assessment) every 4 months during treatment and initiation of thyroid hormone replacement as clinically indicated.[2]

Table 5: Common and Serious Adverse Reactions Associated with Apalutamide

Adverse Reaction Category	Reaction	Incidence (All Grades) Examples	Notes	Source(s)
Common (≥10%)	Fatigue	~39% (TITAN)	A very common side effect of AR-targeted therapy.	13
	Hypertension	~18-25%	Requires monitoring and management of blood pressure.	13
	Rash	~25-28%	A signature toxicity. Most cases are grade 1-2. Grade 3-4 occurs in ~6%.	13
	Diarrhea	~20%	Generally manageable with supportive care.	13
	Arthralgia (Joint Pain)	~16-17%	Common musculoskeletal complaint.	13
	Fall	~12-16%	Significantly increased risk vs. placebo. Requires fall risk assessment.	18
	Fracture	~11-12%	Significantly increased risk vs. placebo. Requires bone health monitoring.	18
Serious (Warnings)	Ischemic Cardiovascular & Cerebrovascular Events	~4%	Includes MI and stroke; some fatal. Requires monitoring and risk factor management.	18
	Seizure	~0.4%	Rare but serious. Permanently discontinue if seizure occurs.	18
	Severe Cutaneous Adverse Reactions (SCARs)	Rare	Includes SJS/TEN and DRESS. Potentially fatal. Permanently discontinue.	30
	Interstitial Lung Disease (ILD)/Pneumonitis	Rare	Potentially fatal. Permanently discontinue.	30
	Hypothyroidism	~8%	Requires TSH monitoring every 4 months.	30

VIII. Drug-Drug Interaction Profile and Clinical Management

The management of drug-drug interactions (DDIs) is a critical aspect of ensuring the safety and efficacy of apalutamide, particularly given that the target patient population is often elderly and receiving multiple concomitant medications for comorbidities. Apalutamide has a significant DDI profile, acting as both a substrate of metabolic enzymes and, more importantly, as a potent inducer of several key enzymes and transporters.

Apalutamide as a Metabolic Substrate

Apalutamide itself is a "victim" of potential DDIs. Its plasma concentration can be altered by other drugs that affect its metabolic pathways.

• Metabolizing Enzymes: As established, apalutamide and its active metabolite are metabolized by CYP2C8 and CYP3A4.[2]
• Effect of Inhibitors: Co-administration of apalutamide with a strong inhibitor of CYP2C8 (e.g., gemfibrozil) or CYP3A4 (e.g., itraconazole, clarithromycin) is predicted to increase the plasma exposure of the active moieties (apalutamide plus N-desmethylapalutamide). While dose adjustments are not explicitly mandated, this increased exposure could heighten the risk of adverse reactions, and caution is advised.[15]

Apalutamide as a Potent Enzyme and Transporter Inducer

The more clinically significant and challenging aspect of apalutamide's DDI profile is its role as a "perpetrator" of interactions. It potently induces the activity of several metabolic pathways, which can dramatically reduce the concentrations and effectiveness of other drugs.

• Enzyme Induction: Apalutamide is classified as a strong inducer of CYP3A4 and CYP2C19, and a weak inducer of CYP2C9.[2]
• Transporter Induction: It also induces the expression and activity of key drug transporters, including P-glycoprotein (P-gp), Breast Cancer Resistance Protein (BCRP), and Organic Anion Transporting Polypeptide 1B1 (OATP1B1).[2]
• Clinical Consequence: This broad and potent induction means that apalutamide can accelerate the clearance and thereby reduce the systemic exposure of a wide array of co-administered drugs that are substrates for these enzymes and transporters. This can lead to a partial or complete loss of efficacy for the affected medication. The European Medicines Agency labeling contains a stark warning: "Apalutamide is a potent enzyme inducer and may lead to loss of efficacy of many commonly used medicinal products".[36]

The clinical challenge posed by this induction profile is substantial. Patients with prostate cancer are typically older and often have comorbidities such as hypertension, dyslipidemia, atrial fibrillation, or diabetes, requiring chronic treatment with medications like statins, certain antihypertensives, direct oral anticoagulants, or anti-diabetic agents. Many of these commonly used drugs are substrates of CYP3A4 or the induced transporters. Initiating apalutamide without a meticulous review and adjustment of concomitant medications could silently render these vital therapies sub-therapeutic, potentially leading to serious consequences such as a stroke, a cardiovascular event, or uncontrolled diabetes. This highlights that the "perpetrator" aspect of apalutamide's DDI profile represents a greater clinical management burden than its "victim" aspect, demanding proactive and continuous pharmacovigilance from the prescribing clinician and pharmacist. A thorough review of all concomitant medications, including prescription, over-the-counter, and herbal products, is mandatory upon initiation of apalutamide and whenever a new medication is added.

Table 6: Clinically Significant Drug-Drug Interactions with Apalutamide

Interaction Type	Interacting Agent Class	Example(s)	Clinical Consequence on Other Drug	Management Recommendation	Source(s)
Apalutamide Affects Other Drugs (Induction)	Substrates of CYP3A4 (Strong Induction)	Certain statins (simvastatin, atorvastatin), calcium channel blockers, opioids (fentanyl), direct oral anticoagulants (rivaroxaban, apixaban), midazolam	Decreased concentration and loss of efficacy	Avoid co-administration where possible. If necessary, monitor for lack of efficacy and consider dose increases of the substrate drug.	2
	Substrates of CYP2C19 (Strong Induction)	Omeprazole, clopidogrel, diazepam	Decreased concentration and loss of efficacy	Avoid co-administration where possible. Monitor for lack of efficacy.	2
	Substrates of CYP2C9 (Weak Induction)	Warfarin, phenytoin	Decreased concentration and loss of efficacy	Monitor for efficacy (e.g., INR for warfarin) and consider dose adjustments.	2
	Substrates of P-gp, BCRP, OATP1B1	Digoxin, rosuvastatin, fexofenadine	Decreased concentration and loss of efficacy	Monitor for efficacy and consider dose adjustments of the substrate drug.	2
Other Drugs Affect Apalutamide	Strong CYP2C8 Inhibitors	Gemfibrozil	Increased concentration of apalutamide active moieties	If co-administration is necessary, reduce the apalutamide dose. Monitor closely for apalutamide-related adverse events.	15
	Strong CYP3A4 Inhibitors	Itraconazole, clarithromycin	Increased concentration of apalutamide active moieties	If co-administration is necessary, reduce the apalutamide dose. Monitor closely for apalutamide-related adverse events.	15

IX. Dosage, Administration, and Special Populations

The practical application of apalutamide in the clinic requires adherence to specific guidelines for dosing, administration, dose modification in response to toxicity, and use in specific patient populations. These guidelines are designed to maximize efficacy while ensuring patient safety.

Standard Dosing and Administration

• Recommended Dose: The standard recommended dose of apalutamide is 240 mg, administered orally once daily.[13] This dose can be administered as a single 240 mg tablet or as four 60 mg tablets.[13]
• Concurrent Therapy: Treatment with apalutamide must be accompanied by continuous androgen deprivation. This is achieved either through the concurrent administration of a gonadotropin-releasing hormone (GnRH) analog (e.g., leuprolide, goserelin) or through prior surgical castration (bilateral orchiectomy).[2]
• Administration with Food: As apalutamide's absorption is not significantly affected by food, it can be taken with or without meals, providing flexibility for the patient.[13]
• Tablet Integrity: The tablets should be swallowed whole and should not be crushed or split.[13]

Dose Modifications for Adverse Reactions

To manage treatment-related toxicities, a clear dose modification strategy is outlined in the prescribing information.

• Dose Interruption: If a patient experiences a Grade 3 or greater adverse reaction, or any other intolerable side effect, dosing with apalutamide should be withheld until the symptoms improve to Grade 1 or less, or return to their original baseline grade.[13]
• Dose Reduction: Once the toxicity has resolved, treatment can be resumed. Depending on the nature and severity of the event, the clinician may resume at the same 240 mg dose or at a reduced dose of 180 mg or 120 mg once daily, if warranted.[13]
• Permanent Discontinuation: For certain severe, life-threatening toxicities, permanent discontinuation of apalutamide is required. These include confirmed SCARs (e.g., SJS/TEN), severe ILD/pneumonitis, or Grade 3-4 cerebrovascular and ischemic cardiovascular events.[13]

Alternate Methods of Administration

Recognizing that the target patient population often includes elderly individuals who may have difficulty swallowing (dysphagia) or require enteral feeding, the labeling for apalutamide provides detailed, validated instructions for alternative administration methods. This patient-centric approach enhances the drug's utility and accessibility.

• Oral Dispersion: For patients unable to swallow the tablets whole, the entire prescribed dose can be dispersed in various media. The tablets are placed in a cup with a small amount of non-carbonated water and allowed to break up, then stirred. The resulting mixture can then be combined with orange juice, applesauce, green tea, or drinkable yogurt and swallowed immediately. The cup should be rinsed with additional liquid to ensure the full dose is administered.[13]
• Feeding Tube Administration: Apalutamide can also be administered via a nasogastric (NG) or other feeding tube (8 French or larger). Specific instructions involve placing the tablets in a syringe, adding water, waiting for dispersion, and then administering through the tube, followed by a water flush.[13]

Use in Specific Populations

• Renal and Hepatic Impairment: No initial dose adjustment is required for patients with mild-to-moderate renal impairment (eGFR 30-89 mL/min/1.73 m²) or mild-to-moderate hepatic impairment. However, apalutamide has not been formally evaluated in patients with severe renal impairment (eGFR <30), end-stage renal disease, or severe hepatic impairment (Child-Pugh Class C), and therefore should be used with caution in these populations.[15]
• Females and Reproduction: Apalutamide is not indicated for use in females. Based on its mechanism of action and findings in animal studies, it can cause harm to a developing fetus and loss of pregnancy. Therefore, it is contraindicated in women who are or may become pregnant.[18]
• Contraception: Males with female partners of reproductive potential must use effective contraception (e.g., a condom plus another highly effective method) during treatment and for 3 months following the final dose of apalutamide.[18]
• Sperm Donation: Patients should not donate sperm during treatment and for 3 months after the last dose.[31]

X. Comparative Analysis: Apalutamide in the Context of Second-Generation Antiandrogens

Apalutamide belongs to a class of highly effective second-generation AR inhibitors that also includes enzalutamide (Xtandi) and darolutamide (Nubeqa). As there are no large-scale, head-to-head randomized trials directly comparing these agents, clinical decision-making relies on cross-trial comparisons, network meta-analyses, real-world evidence, and a detailed examination of their distinct pharmacological profiles. The choice between them represents a classic clinical scenario of balancing efficacy against tolerability for the individual patient.

Pharmacokinetic and Dosing Comparison

The three agents exhibit key differences in their pharmacokinetics, which directly influence their dosing schedules and interaction potential.

• Bioavailability and Food Effect: Apalutamide and enzalutamide both have high oral bioavailability (100% for apalutamide) and can be taken once daily without regard to food. In contrast, darolutamide has a low absolute bioavailability (~30%) that increases 2- to 2.5-fold when taken with a meal. Consequently, darolutamide must be administered with food to ensure adequate absorption.[15]
• Half-life and Dosing Frequency: Apalutamide (t½ ≈ 3-4 days) and enzalutamide (t½ ≈ 5.8 days) possess long elimination half-lives, which supports convenient once-daily dosing. Darolutamide has a much shorter half-life of approximately 20 hours, necessitating a twice-daily dosing regimen.[15]
• CNS Penetration: A crucial structural and pharmacokinetic differentiator is CNS penetration. Darolutamide was specifically designed to have markedly lower penetration across the blood-brain barrier compared to both apalutamide and enzalutamide. This property is believed to be the primary reason for its more favorable CNS safety profile.[15]

Comparative Efficacy

In the nmCRPC setting, all three agents have demonstrated robust and statistically significant improvements in metastasis-free survival compared to placebo in their respective pivotal trials (SPARTAN for apalutamide, PROSPER for enzalutamide, and ARAMIS for darolutamide).[15]

• A formal network meta-analysis of these three trials was conducted to provide an indirect comparison of their efficacy. The analysis suggested that apalutamide and enzalutamide may offer a statistically significant, though modest, MFS benefit over darolutamide in nmCRPC. In this analysis, apalutamide had the highest probability (P-score: 0.88) of being the most effective agent for prolonging MFS, followed closely by enzalutamide.[38]
• In the mCSPC setting, both apalutamide (TITAN) and enzalutamide (ENZAMET, ARCHES) have demonstrated significant improvements in overall survival and/or progression-free survival when added to ADT.[15] Darolutamide has also shown a survival benefit in this setting when added to a regimen of ADT plus docetaxel.[15]

Comparative Safety and Tolerability

While all three drugs are generally well-tolerated, their safety profiles exhibit important differences that heavily influence treatment selection.

• Overall Tolerability: Across clinical trials and emerging real-world evidence (e.g., the DEAR studies), darolutamide appears to have the most favorable overall tolerability profile. Real-world studies have shown lower rates of treatment discontinuation due to adverse events for darolutamide compared to apalutamide and enzalutamide.[37]
• Specific Adverse Events:
• CNS Effects (Seizures, Falls, Fatigue): Darolutamide has the lowest risk of CNS-related side effects, which is consistent with its low blood-brain barrier penetration. The incidence of seizure in its pivotal trial was the same as placebo.[15] Both apalutamide and enzalutamide carry a higher risk of falls and fatigue.[15]
• Rash: The incidence of rash is notably higher with apalutamide compared to both enzalutamide and darolutamide, representing a signature toxicity of the agent.[15]
• Hypertension: Is a common adverse event associated with all three drugs.[15]
• Drug-Drug Interactions (DDIs): This is a major point of differentiation. Both apalutamide and enzalutamide are potent inducers of CYP enzymes and can cause numerous clinically significant DDIs. Darolutamide has a much lower potential for CYP-mediated DDIs, making it a simpler agent to manage in patients on multiple concomitant medications.[15]

The choice of agent is therefore highly dependent on the individual patient's clinical profile. For a younger, robust patient with few comorbidities and no interacting medications, a clinician might prioritize the potential marginal efficacy benefit suggested for apalutamide by the network meta-analysis. Conversely, for an older, frailer patient with a history of falls or seizures, cognitive concerns, or who is taking multiple medications that could interact, the superior safety, tolerability, and lower DDI potential of darolutamide would likely make it the preferred choice. This nuanced framework moves beyond declaring one drug universally "better" and instead promotes a personalized medicine approach within the class.

Table 7: Comparative Profile of Second-Generation Antiandrogens: Apalutamide vs. Enzalutamide vs. Darolutamide

Feature	Apalutamide (Erleada)	Enzalutamide (Xtandi)	Darolutamide (Nubeqa)
Dosing Schedule	240 mg once daily	160 mg once daily	600 mg (2x 300 mg tablets) twice daily
Food Effect	None; can be taken with or without food	None; can be taken with or without food	Must be taken with food (absorption increases >2-fold)
CNS Penetration	Low / Limited	High	Very Low (structurally distinct)
Efficacy (nmCRPC MFS HR vs Placebo)	0.28 (SPARTAN)	0.29 (PROSPER)	0.41 (ARAMIS)
Key Safety/Tolerability Issues	- Rash (notably higher incidence) - Falls & Fractures - Fatigue, Hypertension - Seizure risk (~0.4%)	- Fatigue (prominent) - Falls & Fractures - Hypertension - Seizure risk (~0.5-0.9%)	- Favorable tolerability - Fatigue (lower incidence) - Seizure risk similar to placebo (<0.2%)
Drug-Drug Interaction Potential	Strong Inducer of CYP3A4, CYP2C19; Weak Inducer of CYP2C9	Strong Inducer of CYP3A4; Moderate Inducer of CYP2C9, CYP2C19	Minimal CYP Induction; primarily a BCRP/OATP substrate/inhibitor

Data compiled from sources.[15]

XI. Regulatory and Clinical Practice Synopsis

Apalutamide's journey from a promising investigational compound to a global standard of care was marked by key regulatory milestones and rapid incorporation into clinical practice guidelines, reflecting the significant unmet need it addressed and the strength of its supporting clinical data.

Regulatory Milestones

• U.S. FDA Approval (nmCRPC): On February 14, 2018, the FDA granted accelerated approval to apalutamide for the treatment of patients with nmCRPC. This was a historic approval for several reasons: it was the first-ever therapy approved specifically for this disease state, and it was granted under the FDA's Priority Review program. The approval was based on the robust MFS benefit demonstrated in the SPARTAN trial and was notable for the FDA's acceptance of MFS as a primary endpoint for approval in this setting.[1]
• U.S. FDA Approval (mCSPC): On September 17, 2019, the FDA expanded apalutamide's indication to include the treatment of patients with mCSPC. This approval was based on the compelling overall survival and radiographic progression-free survival data from the TITAN trial and was also granted Priority Review, underscoring the significant therapeutic advance it represented.[24]
• European Medicines Agency (EMA) Approval: Following positive opinions from the Committee for Medicinal Products for Human Use (CHMP), apalutamide received marketing authorization from the EMA for use in the European Union for both high-risk nmCRPC and mHSPC (the European equivalent of mCSPC). These approvals were based on the same pivotal SPARTAN and TITAN trial data, establishing apalutamide as a standard of care across Europe.[32]

Placement in Clinical Practice Guidelines

The strength and consistency of the evidence from the SPARTAN and TITAN trials led to the rapid incorporation of apalutamide into major international clinical practice guidelines.

• The National Comprehensive Cancer Network (NCCN), whose guidelines are highly influential in oncology practice in the United States and globally, recommends apalutamide as a Category 1 treatment option (the highest level of evidence and uniform consensus) for patients with both nmCRPC (specifically those with a PSADT ≤10 months) and mCSPC.[15] This solidifies its role as a preferred, evidence-based standard of care in advanced prostate cancer.

The rapid sequence of approvals for apalutamide, followed closely by its competitors enzalutamide and darolutamide for similar indications, quickly created a dynamic and hyper-competitive market for second-generation AR inhibitors. This intense competition has been a powerful driver for post-approval research aimed at differentiating the agents. With all three drugs demonstrating robust, but broadly similar, efficacy in their pivotal trials, the basis for clinical and commercial competition has shifted towards other attributes. This is evident in the heavy focus on health-related quality of life outcomes in the TITAN trial analysis and the emergence of real-world evidence studies, like the DEAR series, which are specifically designed to compare tolerability, safety, and treatment discontinuation rates in routine clinical practice. This dynamic illustrates how the regulatory and commercial environment has directly shaped the subsequent clinical research agenda for the entire drug class, with the ultimate goal of helping clinicians better tailor therapy to individual patients.

XII. Expert Synthesis and Future Directions

Apalutamide has unequivocally established itself as a major therapeutic advance in the management of advanced prostate cancer. Its development and approval have not only provided patients with a life-extending treatment option but have also reshaped the clinical and regulatory landscape for the disease.

Integrated Summary of Value Proposition

The value of apalutamide is multi-faceted. It is a highly effective androgen receptor inhibitor that provides a comprehensive blockade of the AR signaling pathway. This potent mechanism translated directly into statistically significant and clinically meaningful improvements in survival in two distinct, critical disease states: non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). Its excellent pharmacokinetic profile, featuring high bioavailability and a long half-life, affords the convenience of once-daily oral dosing without regard to meals, promoting patient adherence. However, its potent pharmacology is accompanied by a distinct safety profile that requires diligent clinical management. The key toxicities to monitor and manage include a notable incidence of rash, an increased risk of falls and fractures necessitating a holistic approach to patient frailty and bone health, and a rare but serious risk of seizure. Furthermore, its powerful induction of major metabolic enzymes creates a significant potential for drug-drug interactions, mandating a thorough and continuous review of all concomitant medications to avoid loss of their efficacy.

Unanswered Questions and Future Research

While apalutamide is now a cornerstone of therapy, several critical questions remain, and research is actively moving in new directions to further optimize treatment for prostate cancer.

• Personalization of Therapy: A crucial unmet need is the development and validation of predictive biomarkers. Currently, the choice between apalutamide, enzalutamide, and darolutamide is based on clinical factors and tolerability profiles. The future lies in identifying molecular markers—such as AR splice variants (e.g., AR-V7), circulating tumor DNA (ctDNA) signatures, or specific gene expression profiles—that can predict which patients will derive the most benefit from apalutamide versus other AR inhibitors, chemotherapy, or other classes of therapy like PARP inhibitors.[17]
• Expansion to Earlier Disease States: The profound efficacy demonstrated in advanced and metastatic disease has logically prompted investigation into earlier stages of prostate cancer. Trials are underway or planned to evaluate the role of apalutamide in settings such as high-risk localized prostate cancer following definitive therapy (as suggested by a trial mentioned in [40]) and in the neoadjuvant setting before surgery or radiation, with the goal of improving cure rates.
• Novel Combination Therapies: To overcome primary and acquired resistance to AR-directed therapy, the next frontier is combination strategies. Clinical trials are actively exploring the combination of apalutamide with other targeted agents. This includes combinations with PARP inhibitors (e.g., saruparib, talazoparib) for patients with DNA repair defects, and with immunotherapy agents (e.g., PD-1 inhibitors like cetrelimab) in an attempt to potentiate an anti-tumor immune response.[44]
• Dose Optimization: Early phase trials of second-generation AR inhibitors often showed anti-tumor activity across a range of doses. Given that some toxicities are dose-related, there is an interest in exploring whether lower, personalized doses of apalutamide could maintain efficacy while improving tolerability, particularly in older or frailer patient populations.[46]

Final Expert Opinion

Apalutamide represents a landmark achievement in oncology drug development. Its legacy will be defined not only by the substantial survival benefits demonstrated in the SPARTAN and TITAN trials but also by its pivotal role in establishing metastasis-free survival as a valid regulatory endpoint, a precedent that has accelerated progress for an entire class of drugs and benefited countless patients. It is a cornerstone of modern therapy for advanced prostate cancer. The future of the field will now evolve beyond the current, largely "one-size-fits-all" approach to AR inhibition. The next wave of progress will be driven by a more personalized strategy, where the selection of apalutamide or its alternatives is guided first by nuanced clinical judgment based on patient-specific factors, and ultimately, by validated predictive molecular biomarkers that can direct the right drug to the right patient at the right time.

Works cited

1. Apalutamide: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed August 2, 2025, https://go.drugbank.com/drugs/DB11901
2. Apalutamide - Wikipedia, accessed August 2, 2025, https://en.wikipedia.org/wiki/Apalutamide
3. en.wikipedia.org, accessed August 2, 2025, https://en.wikipedia.org/wiki/Apalutamide#:~:text=Apalutamide%20is%20marketed%20under%20the%20brand%20names%20Erleada%20and%20Erlyand.
4. Apalutamide - brand name list from Drugs.com, accessed August 2, 2025, https://www.drugs.com/ingredient/apalutamide.html
5. Apalutamide (ARN-509) | 99.98%(HPLC) | Androgen Receptor inhibitor - Selleckchem.com, accessed August 2, 2025, https://www.selleckchem.com/products/arn-509.html
6. ARN-509 (JNJ-56021927, CAS Number: 956104-40-8) | Cayman Chemical, accessed August 2, 2025, https://www.caymanchem.com/product/17132/
7. Apalutamide | JNJ-56021927 | ARN-509 | CAS#956104-40-8 - MedKoo Biosciences, accessed August 2, 2025, https://www.medkoo.com/products/4577
8. Definition of apalutamide - NCI Drug Dictionary, accessed August 2, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/apalutamide
9. ERLEADA™ (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Granted U.S. FDA Approval for the Treatment of Patients with Non-Metastatic Castration-Resistant Prostate Cancer, accessed August 2, 2025, https://www.jnj.com/media-center/press-releases/erleada-apalutamide-a-next-generation-androgen-receptor-inhibitor-granted-us-fda-approval-for-the-treatment-of-patients-with-non-metastatic-castration-resistant-prostate-cancer
10. A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN) - ClinicalTrials.gov, accessed August 2, 2025, https://clinicaltrials.gov/study/NCT01946204
11. Apalutamide | C21H15F4N5O2S | CID 24872560 - PubChem, accessed August 2, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/24872560
12. Apalutamide (Amorphous & Form B), 956104-40-8 | BroadPharm, accessed August 2, 2025, https://broadpharm.com/product/bp-43625
13. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights ..., accessed August 2, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210951s016lbl.pdf
14. Apalutamide (ARN-509) | AR Antagonist - MedchemExpress.com, accessed August 2, 2025, https://www.medchemexpress.com/ARN-509.html
15. Comparison of Second-Generation Antiandrogens for the Treatment ..., accessed August 2, 2025, https://jhoponline.com/issue-archive/2022-issues/april-2022-vol-12-no-2/comparison-of-second-generation-antiandrogens-for-the-treatment-of-prostate-cancer
16. Erleada (Apalutamide) First Drug Approved by the FDA for Nonmetastatic Castration-Resistant Prostate Cancer, accessed August 2, 2025, https://www.ahdbonline.com/issues/2019/march-2019-vol-12-tenth-annual-payers-guide/erleada-apalutamide-first-drug-approved-by-the-fda-for-nonmetastatic-castration-resistant-prostate-cancer
17. A TITAN step forward: apalutamide for metastatic castration-sensitive prostate cancer - Kwon, accessed August 2, 2025, https://atm.amegroups.org/article/view/29150/html
18. ERLEADA® (apalutamide) tablets, for oral use - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed August 2, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210951s001lbl.pdf
19. FDA approves apalutamide for non-metastatic castration-resistant ..., accessed August 2, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-apalutamide-non-metastatic-castration-resistant-prostate-cancer
20. Updated Results of the SPARTAN Study Show 25 Percent ..., accessed August 2, 2025, https://www.jnj.com/media-center/press-releases/updated-results-of-the-spartan-study-show-25-percent-reduction-in-the-risk-of-death-in-patients-with-non-metastatic-castration-resistant-prostate-cancer-nmcrpc-treated-with-erleada-apalutamide
21. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer - PubMed, accessed August 2, 2025, https://pubmed.ncbi.nlm.nih.gov/29420164/
22. Final Survival Results From SPARTAN, a Phase 3 Study of Apalutamide Versus Placebo in Patients With Nonmetastatic Castration-Resistant Prostate Cancer - Beyond the Abstract - UroToday, accessed August 2, 2025, https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/127174-final-survival-results-from-spartan-a-phase-3-study-of-apalutamide-versus-placebo-in-patients-with-nonmetastatic-castration-resistant-prostate-cancer.html
23. Apalutamide and Overall Survival in Prostate Cancer - PubMed, accessed August 2, 2025, https://pubmed.ncbi.nlm.nih.gov/32907777/
24. FDA approves apalutamide for metastatic castration-sensitive prostate cancer, accessed August 2, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-apalutamide-metastatic-castration-sensitive-prostate-cancer
25. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study - PubMed, accessed August 2, 2025, https://pubmed.ncbi.nlm.nih.gov/31578173/
26. A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC | ClinicalTrials.gov, accessed August 2, 2025, https://clinicaltrials.gov/study/NCT02489318
27. Apalutamide in Patients With Metastatic Castration-Sensitive ..., accessed August 2, 2025, https://ascopubs.org/doi/10.1200/JCO.20.03488
28. TITAN trial; shifting focus from hormone-refractory to hormone-sensitive prostate cancer - PMC - PubMed Central, accessed August 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7279108/
29. Apalutamide Treatment for Metastatic Castration-Sensitive Prostate Cancer and Health-Related Quality of Life - The ASCO Post, accessed August 2, 2025, https://ascopost.com/issues/november-10-2019/apalutamide-treatment-for-metastatic-castration-sensitive-prostate-cancer-and-health-related-quality-of-life/
30. The Official HCP Website | ERLEADA® (apalutamide) HCP, accessed August 2, 2025, https://www.erleadahcp.com/
31. Official Patient Website | ERLEADA® (apalutamide), accessed August 2, 2025, https://www.erleada.com/
32. Erleada | European Medicines Agency (EMA), accessed August 2, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/erleada
33. ERLEADA® (apalutamide) tablets, for oral use - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed August 2, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210951s007lbl.pdf
34. Updated Results of the SPARTAN Study Show 25 Percent Reduction in the Risk of Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) Treated with ERLEADA® (apalutamide) - PR Newswire, accessed August 2, 2025, https://www.prnewswire.com/news-releases/updated-results-of-the-spartan-study-show-25-percent-reduction-in-the-risk-of-death-in-patients-with-non-metastatic-castration-resistant-prostate-cancer-nmcrpc-treated-with-erleada-apalutamide-300926853.html
35. Dosing | ERLEADA® (apalutamide) HCP, accessed August 2, 2025, https://www.erleadahcp.com/dosing/
36. Erleada, INN - apalutamide - EMA, accessed August 2, 2025, https://www.ema.europa.eu/en/documents/product-information/erleada-epar-product-information_en.pdf
37. Darolutamide, Enzalutamide, and Apalutamide for Nonmetastatic Castration-Resistant Prostate Cancer Patients in the United States (DEAR): Comparative Real-World Evidence - Journal of Hematology Oncology Pharmacy, accessed August 2, 2025, https://jhoponline.com/issue-archive/2024-issues/march-2024-vol-14-special-feature/darolutamide-enzalutamide-and-apalutamide-for-nonmetastatic-castration-resistant-prostate-cancer-patients-in-the-united-states-dear-comparative-real-world-evidence
38. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis - PubMed Central, accessed August 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7572325/
39. Real-world use and outcomes of darolutamide (DARO), enzalutamide (ENZA), and apalutamide (APA) for nonmetastatic castration-resistant prostate cancer (nmCRPC): Race subgroup analysis. - ASCO Publications, accessed August 2, 2025, https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.158
40. Erleada (apalutamide) FDA Approval History - Drugs.com, accessed August 2, 2025, https://www.drugs.com/history/erleada.html
41. Janssen Seeks to Expand Use of ERLEADA® (apalutamide) in the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer - BioSpace, accessed August 2, 2025, https://www.biospace.com/janssen-seeks-to-expand-use-of-erleada-apalutamide-in-the-treatment-of-patients-with-metastatic-hormone-sensitive-prostate-cancer
42. Erleada (apalutamide) gets positive opinion from the EMA | Approvals - Everyone.org, accessed August 2, 2025, https://everyone.org/blog/erleada-apalutamide-gets-positive-opinion-from-the-ema
43. J&J gets EMA nod for wider use of Erleada in prostate cancer - PMLiVE, accessed August 2, 2025, https://pmlive.com/pharma_news/j_and_j_gets_ema_nod_for_wider_use_of_erleada_in_prostate_cancer_1323769/
44. Apalutamide Completed Phase 1 Trials for Castration Resistant Prostatic Neoplasms Treatment | DrugBank Online, accessed August 2, 2025, https://go.drugbank.com/drugs/DB11901/clinical_trials?conditions=DBCOND0129140&phase=1&purpose=treatment&status=completed
45. Apalutamide Recruiting Phase 1 Trials for Metastatic Prostate Cancer Treatment - DrugBank, accessed August 2, 2025, https://go.drugbank.com/drugs/DB11901/clinical_trials?conditions=DBCOND0033188&phase=1&purpose=treatment&status=recruiting
46. Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid review | BMJ Oncology, accessed August 2, 2025, https://bmjoncology.bmj.com/content/3/1/e000198